Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 6, 2014, Pages 1292-1298

  Yuan, Jianye ^a,b   Baker, Susan S ^a   Liu, Wensheng ^a   Alkhouri, Razan ^a   Baker, Robert D ^a   Xie, Jianqun ^b   Ji, Guang ^b   Zhu, Lixin ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Endotoxin; Gram negative; Lipopolysaccharide; Microbiome

Indexed keywords

ENDOTOXIN; RNA 16S;

ACIDOBACTERIA; ACTINOBACTERIA; ADOLESCENT; ARTICLE; BACTEROIDETES; CELL LYSATE; CHLAMYDIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTOXEMIA; EURYARCHAEOTA; FEMALE; FIRMICUTES; FUSOBACTERIA; GRAM NEGATIVE BACTERIUM; HUMAN; INCIDENCE; INTESTINE FLORA; LIVER BIOPSY; LIVER FIBROSIS; MALE; METHANOBREVIBACTER; MICROBIOME; MOLLICUTES; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PLANCTOMYCETES; PRIORITY JOURNAL; PROTEOBACTERIA; SPIROCHETE; VERRUCOMICROBIA; BLOOD; CHILD; COMPLICATION; INTESTINE; ISOLATION AND PURIFICATION; MICROBIOLOGY; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADOLESCENT; CHILD; ENDOTOXEMIA; ENDOTOXINS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; INCIDENCE; INTESTINES; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84900538053     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12510     Document Type: Article

References (39)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011; 34: 274-285.
2. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
3. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl Acad. Sci. USA 1997; 94: 2557-2562.
4. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.
5. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J. Gastroenterol. Hepatol. 2009; 24: 943-954.
6. Volynets V, Kuper MA, Strahl S etal. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig. Dis. Sci. 2012; 57: 1932-1941.
7. Harte AL, da Silva NF, Creely SJ etal. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. (Lond.) 2010; 7: 15.
8. Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2010; 50: 645-649.
9. Ruiz AG, Casafont F, Crespo J etal. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 2007; 17: 1374-1380.
10. Verdam FJ, Rensen SS, Driessen A, Greve JW, Buurman WA. Novel evidence for chronic exposure to endotoxin in human nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2011; 45: 149-152.
11. Zhu L, Baker SS, Gill C etal. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609.
12. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
14. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE 2012; 7: e39504.
15. Krieg NR, Staley JT, Brown DR etal. Bergey's Manual of Systematic Bacteriology, The Bacteroidetes, Spirochaetes, Tenericutes (Mollicutes), Acidobacteria, Fibrobacteres, Fusobacteria, Dictyoglomi, Gemmatimonadetes, Lentisphaerae, Verrucomicrobia, Chlamydiae, and Planctomycetes, 2nd edn. New York: Springer, 2011.
16. Hugenholtz P, Hooper SD, Kyrpides NC. Focus: Synergistetes. Environ. Microbiol. 2009; 11: 1327-1329.
17. Prescott LM, Harley JP, Klein DA. Chapter 19: microbial taxonomy. In: Microbiology, 5th edn. New York: The McGraw-Hill Companies, 2002; 421-449.
18. Glockner J, Kube M, Shrestha PM etal. Phylogenetic diversity and metagenomics of candidate division OP3. Environ. Microbiol. 2010; 12: 1218-1229.
19. Cho JC, Vergin KL, Morris RM, Giovannoni SJ. Lentisphaera araneosa gen. nov., sp. nov, a transparent exopolymer producing marine bacterium, and the description of a novel bacterial phylum, Lentisphaerae. Environ. Microbiol. 2004; 6: 611-621.
20. Bennett KW, Eley A. Fusobacteria: new taxonomy and related diseases. J. Med. Microbiol. 1993; 39: 246-254.
21. Hugenholtz P, Tyson GW, Webb RI, Wagner AM, Blackall LL. Investigation of candidate division TM7, a recently recognized major lineage of the domain Bacteria with no known pure-culture representatives. Appl. Environ. Microbiol. 2001; 67: 411-419.
22. Miller TL, Lin C. Description of Methanobrevibacter gottschalkii sp. nov., Methanobrevibacter thaueri sp. nov., Methanobrevibacter woesei sp. nov. and Methanobrevibacter wolinii sp. nov. Int. J. Syst. Evol. Microbiol. 2002; 52: 819-822.
23. Miele L, Valenza V, La Torre G etal. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
24. Thuy S, Ladurner R, Volynets V etal. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 2008; 138: 1452-1455.
25. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE 2010; 5: e9570.
26. Schwiertz A, Taras D, Schafer K etal. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 2010; 18: 190-195.
27. Zhang H, DiBaise JK, Zuccolo A etal. Human gut microbiota in obesity and after gastric bypass. Proc. Natl Acad. Sci. USA 2009; 106: 2365-2370.
28. Vrieze A, Van Nood E, Holleman F etal. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-967.
29. Michail S, Kenche H, Homer DC, Reo N. Gut microbial profile in pediatric non-alcoholic fatty liver disease. Gastroenterology 2011; 140: S-118.
30. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023.
31. El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig. Dis. Sci. 2008; 53: 2307-2312.
32. Howell MD, Novack V, Grgurich P etal. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 2010; 170: 784-790.
33. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch. Intern. Med. 2010; 170: 772-778.
34. Dial MS. Proton pump inhibitor use and enteric infections. Am. J. Gastroenterol. 2009; 104 (Suppl. 2): S10-16.
35. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 2007; 102: 2047-2056; quiz 57.
36. Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000; 119: 1340-1347.
37. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010; 11: 467-478.
38. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945.
39. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846.